194 related articles for article (PubMed ID: 30177030)
1. Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.
Lee DJ; Barocas DA; Zhao Z; Huang LC; Koyama T; Resnick MJ; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
Pract Radiat Oncol; 2018; 8(5):307-316. PubMed ID: 30177030
[TBL] [Abstract][Full Text] [Related]
2. Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer.
Swisher-McClure S; Mitra N; Woo K; Smaldone M; Uzzo R; Bekelman JE
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):103-12. PubMed ID: 24725694
[TBL] [Abstract][Full Text] [Related]
3. [Status report of Hungarian radiotherapy based on treatment data, available infrastucture, and human resources].
Polgár C; Major T; Király R; Fodor J; Kásler M
Magy Onkol; 2015 Jun; 59(2):85-94. PubMed ID: 26035155
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
6. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.
Cheung AK; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin M; Ross R; D'Amico AV
Brachytherapy; 2010; 9(2):145-50. PubMed ID: 20346894
[TBL] [Abstract][Full Text] [Related]
7. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
9. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.
Panje CM; Dal Pra A; Zilli T; R Zwahlen D; Papachristofilou A; Herrera FG; Matzinger O; Plasswilm L; Putora PM
Strahlenther Onkol; 2015 Oct; 191(10):778-86. PubMed ID: 25986251
[TBL] [Abstract][Full Text] [Related]
10. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
11. Quality indicators for prostate radiotherapy: are patients disadvantaged by receiving treatment in a 'generalist' centre?
Freeman AR; Roos DE; Kim L
J Med Imaging Radiat Oncol; 2015 Apr; 59(2):255-64. PubMed ID: 25345594
[TBL] [Abstract][Full Text] [Related]
12. Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer.
Kalbasi A; Li J; Berman A; Swisher-McClure S; Smaldone M; Uzzo RG; Small DS; Mitra N; Bekelman JE
JAMA Oncol; 2015 Oct; 1(7):897-906. PubMed ID: 26181727
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
15. Current standards and future directions for prostate cancer radiation therapy.
Pinkawa M; Schoth F; Böhmer D; Hatiboglu G; Sharabi A; Song D; Eble MJ
Expert Rev Anticancer Ther; 2013 Jan; 13(1):75-88. PubMed ID: 23259429
[TBL] [Abstract][Full Text] [Related]
16. Decision regret in men undergoing dose-escalated radiation therapy for prostate cancer.
Steer AN; Aherne NJ; Gorzynska K; Hoffman M; Last A; Hill J; Shakespeare TP
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):716-20. PubMed ID: 23608238
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
[TBL] [Abstract][Full Text] [Related]
18. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
[TBL] [Abstract][Full Text] [Related]
19. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
20. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
